Quantcast
Last updated on April 20, 2014 at 8:28 EDT

Latest Neuronetics Stories

2014-01-27 08:28:26

510(k) filing follows recent FDA clearance of CerenaTMS(TM) SUNNYVALE, Calif. and BALTIMORE, Jan. 27, 2014 /PRNewswire/ -- eNeura Inc., a privately held medical technology company, announced today that it filed a 510(k) with the U.S. Food and Drug Administration (FDA) for the SpringTMS(®) transcranial magnetic stimulation (TMS) device. SpringTMS is a second-generation medical device based on eNeura's ground-breaking CerenaTMS(TM), which recently received FDA clearance for the...

2013-09-16 12:27:14

Non-drug Treatment with NeuroStar TMS Led to Significant Symptom Improvement in Patients Not Benefitting from Prior Antidepressant Medication MALVERN, Pa., Sept. 16, 2013 /PRNewswire/ -- Neuronetics, Inc., today announced that results of a naturalistic, observational study from 42 clinical trial sites in the United States, which examined the efficacy of acute treatment with NeuroStar TMS Therapy® in patients with Major Depressive Disorder (MDD), were published in the July 2013 issue...

2013-07-30 08:34:14

Open-label Study will Assess the Safety and Efficacy of NeuroStar Transcranial Magnetic Stimulation (TMS) among Postpartum Patients through One Year MALVERN, Pa., July 30, 2013 /PRNewswire/ -- Neuronetics, Inc., the maker of a non-drug depression treatment, announced today the enrollment of the first five patients in an open-label clinical trial to evaluate NeuroStar TMS Therapy(®) System in women with major depressive disorder (MDD) who experience postpartum symptoms. Postpartum...

2013-05-29 16:25:23

MALVERN, Pa., May 29, 2013 /PRNewswire/ -- Neuronetics, Inc., a privately-held medical device company committed to the development of innovative, non-invasive therapies to treat psychiatric conditions, announced today that it is the recipient of Red Herring's Top 100 North America Award, a prestigious accolade honoring the year's most promising private technology ventures from North America. (Photo: http://photos.prnewswire.com/prnh/20130529/PH22529 ) Neuronetics manufactures and...

2013-05-22 10:36:51

Largest clinical study evaluating durability of Transcranial Magnetic Stimulation shows depression patients maintained remission through 52 weeks with the NeuroStar New data released today at the annual meeting of the American Psychiatric Association show that the NeuroStar TMS Therapy System® induced statistically and clinically meaningful response and remission in patients with Major Depressive Disorder (MDD) during the acute phase of therapy, which were maintained through one year...

2013-05-21 16:28:01

Largest clinical study evaluating durability of Transcranial Magnetic Stimulation (TMS) shows depression patients maintained remission through 52 weeks with the NeuroStar SAN FRANCISCO, May 21, 2013 /PRNewswire/ -- New data released today at the annual meeting of the American Psychiatric Association show that the NeuroStar TMS Therapy System(®) induced statistically and clinically meaningful response and remission in patients with Major Depressive Disorder (MDD) during the acute...

2013-03-19 12:27:30

Study Participants Experienced Improvement in Pain and Well-Being that Persisted Through One Year SAN DIEGO, March 19, 2013 /PRNewswire/ -- New data released today at the annual meeting of the American Academy of Neurology show that transcranial magnetic stimulation (TMS) administered using the NeuroStar TMS Therapy System® significantly reduced pain-related symptoms in patients with Major Depressive Disorder (MDD), with improvement sustained through one year. Pain-related...

2012-10-26 12:06:56

While powerful magnetic stimulation of the frontal lobe of the brain can alleviate symptoms of depression, those receiving the treatment did not report effects on sleep or arousal commonly seen with antidepressant medications, researchers say. "People's sleep gets better as their depression improves, but the treatment doesn't itself cause sedation or insomnia." said Dr. Peter B. Rosenquist, Vice Chair of the Department of Psychiatry and Health Behavior at the Medical College of Georgia at...

2012-10-16 11:26:34

PHILADELPHIA, Oct. 16, 2012 /PRNewswire/ -- Neuronetics, Inc., a privately-held medical device company committed to the development of innovative, non-invasive therapies to treat psychiatric conditions, announced today that its NeuroStar TMS Therapy(®) System has been awarded the prestigious Phoenix 2012 Most Promising New Product Award at the 19(th) annual Phoenix Conference. Phoenix, the Medical Device and Diagnostic Conference for Chief Executive Officers, presents awards each year to...

2012-08-08 23:01:49

TMS NeuroHealth Centers in Tysons Corner was recently featured in a story aired on WJLA-TV on depression treatments in the Washington DC metro area. McLean, Virginia (PRWEB) August 08, 2012 TMS therapy is a newly FDA cleared form of treatment for depression. The story touched on two of TMS NeuroHealth Centers´ patients and how TMS therapy changed their lives. Their story left touching testimonials for all those suffering from depression and provided hope for treatment. TMS therapy...